In this section you will find detailed information regarding the Evotec SE share, ranging from basic share data over stock charts, shareholder structure, our financial analysts, our auditors to our dividend policy.
In this section you will find detailed information regarding the Evotec SE share, ranging from basic share data over stock charts, shareholder structure, our financial analysts, our auditors to our dividend policy.
American Depositary Shares (“ADSs”)
ISIN:
US30050E1055
Ticker symbol
Frankfurt Stock Exchange: EVT
NASDAQ: EVO
Bloomberg Xetra: EVT GY Equity
Reuters Xetra: EVTG.DE
Stock exchange
Nominal capital
Security identification numbers |
|
Listing on Frankfurt Stock Exchange (XETRA) | Ordinary bearer shares ISIN: DE0005664809 |
Listing NASDAQ, New York | American Depositary Shares (“ADSs”) |
Ticker symbol |
|
Listing on Frankfurt Stock Exchange (XETRA) | Frankfurt Stock Exchange: EVT |
Listing NASDAQ, New York | NASDAQ: EVO |
Stock exchange |
|
Listing on Frankfurt Stock Exchange (XETRA) | Frankfurt Stock Exchange |
Listing NASDAQ, New York | NASDAQ New York |
Segment | |
Listing on Frankfurt Stock Exchange (XETRA) | Prime Standard |
Listing NASDAQ, New York | Global Select Market |
Index | |
Listing on Frankfurt Stock Exchange (XETRA) | MDAX, TecDAX, Prime All Share, LTecDAX, Technology All Share, CDAX |
Listing NASDAQ, New York | n/a |
Designated Sponsor | |
Listing on Frankfurt Stock Exchange (XETRA) | ODDO SEYDLER BANK AG |
Listing NASDAQ, New York | |
Paying agent | |
Listing on Frankfurt Stock Exchange (XETRA) | Deutsche Bank AG, Frankfurt am Main |
Listing NASDAQ, New York | J.P. Morgan |
Number of shares issued | |
Listing on Frankfurt Stock Exchange (XETRA) | 177,185,736 ordinary bearer shares |
Listing NASDAQ, New York | 22,995,000 ADSs (11,497,500 ordinary shares) |
Nominal capital |
|
Listing on Frankfurt Stock Exchange (XETRA) | € 177,185,736 |
Listing NASDAQ, New York | € 177,185,736 |
Since November 2021 Evotec SE is listed on NASDAQ (Ticker Symbol: EVO).
Please find all further information regarding the NASDAQ listing as well as al published filings of Evotec SE under the following link:
On 31 August 2023, the number of total voting rights amounts to 177,185,736.
Under the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG), shareholders of a listed German company are required to notify the Company and the German Federal Financial Supervisory Authority (BaFin) of any change to the voting interest in Evotec SE whenever it reaches, exceeds or falls below specified thresholds (3%, 5%, 10%, 15%, 20%, 25%, 30%, 50% or 75% of the voting rights). Evotec’s voting rights announcements can be found at dgap.de.
Three shareholders, Novo Holdings A/S, T. Rowe Price Group Inc. and Mubadala Investment Company, currently hold more than 5% of the shares of Evotec SE. The free float according to the definition of the Frankfurt Stock Exchange is approx. 71% according to our estimates (Evotec: 08|2023).
* Rounding differences may occur.
Below you will find the latest analyst recommendations.
Analyst | Bryan Garnier & Co |
Recommendation | BUY |
Target price of Shares listed at Frankfurt Stock Exchange (in EUR) |
22.00 EUR |
Target Price of ADS listed at NASDAQ New York (in USD) |
- |
Date of latest Research Report |
29 September 2022 |
Analyst | Citigroup Inc. |
Recommendation | BUY |
Target price of Shares listed at Frankfurt Stock Exchange (in EUR) |
31.60 EUR |
Target Price of ADS listed at NASDAQ New York (in USD) |
- |
Date of latest Research Report |
28 July 2023 |
Analyst | TD Cowen |
Recommendation | OUTPERFORM |
Target price of Shares listed at Frankfurt Stock Exchange (in EUR) |
50.00 EUR |
Target Price of ADS listed at NASDAQ New York (in USD) |
28.00 USD |
Date of latest Research Report |
29 August 2023 |
Analyst | Deutsche Bank |
Recommendation | HOLD |
Target price of Shares listed at Frankfurt Stock Exchange (in EUR) |
20.00 EUR |
Target Price of ADS listed at NASDAQ New York (in USD) |
- |
Date of latest Research Report |
31 August 2023 |
Analyst | H.C.Wainwright & Co |
Recommendation | BUY |
Target price of Shares listed at Frankfurt Stock Exchange (in EUR) |
- |
Target Price of ADS listed at NASDAQ New York (in USD) |
14.00 USD |
Date of latest Research Report |
31 August 2023 |
Analyst | Jefferies |
Recommendation | BUY |
Target price of Shares listed at Frankfurt Stock Exchange (in EUR) |
34.00 EUR |
Target Price of ADS listed at NASDAQ New York (in USD) |
- |
Date of latest Research Report |
27 July 2023 |
Analyst | Morgan Stanley |
Recommendation | OVERWEIGHT |
Target price of Shares listed at Frankfurt Stock Exchange (in EUR) |
27.00 EUR |
Target Price of ADS listed at NASDAQ New York (in USD) |
- |
Date of latest Research Report |
04 September 2023 |
Analyst | ODDO BHF |
Recommendation | OUTPERFORM |
Target price of Shares listed at Frankfurt Stock Exchange (in EUR) |
23.00 EUR |
Target Price of ADS listed at NASDAQ New York (in USD) |
- |
Date of latest Research Report |
09 January 2023 |
Analyst | Royal Bank of Canada (RBC) |
Recommendation | OUTPERFORM |
Target price of Shares listed at Frankfurt Stock Exchange (in EUR) |
28.00 EUR |
Target Price of ADS listed at NASDAQ New York (in USD) |
- |
Date of latest Research Report |
29 August 2023 |
Analyst | Rx Securities |
Recommendation | BUY |
Target price of Shares listed at Frankfurt Stock Exchange (in EUR) |
27.00 EUR |
Target Price of ADS listed at NASDAQ New York (in USD) |
- |
Date of latest Research Report |
29 August 2023 |
Analyst | Van Lanschot Kempen |
Recommendation | BUY |
Target price of Shares listed at Frankfurt Stock Exchange (in EUR) |
23.00 EUR |
Target Price of ADS listed at NASDAQ New York (in USD) |
- |
Date of latest Research Report |
29 August 2023 |
Analyst | Warburg Research |
Recommendation | BUY |
Target price of Shares listed at Frankfurt Stock Exchange (in EUR) |
30.00 EUR |
Target Price of ADS listed at NASDAQ New York (in USD) |
- |
Date of latest Research Report |
29 August 2023 |
Analyst | Average target price |
Recommendation | |
Target price of Shares listed at Frankfurt Stock Exchange (in EUR) |
26.38 EUR |
Target Price of ADS listed at NASDAQ New York (in USD) |
21.00 USD |
Date of latest Research Report |
Evotec is covered and evaluated by the analysts mentioned above. Please note that any opinions, estimates or forecasts regarding Evotec's performance made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Evotec or its management. The above reference to the analysts does not imply that Evotec endorses their opinions. Evotec is under no obligation to update or supplement the information provided above and does not guarantee the accuracy or completeness of this list.
Copies of the reports from the analysts listed above can be obtained directly from the analysts or their employers. Due to legal requirements, Evotec is not allowed to publish the analyst reports.
The payment of dividends depends on Evotec’s financial situation and liquidity requirements, general market conditions, and statutory, tax and regulatory requirements.
Evotec has never paid or declared any cash dividends on its ordinary shares, and does not anticipate paying any cash dividends on its ordinary shares in the foreseeable future. Evotec intends to retain all available funds and any future earnings and reinvest them in the company’s further growth strategy to better leverage longterm growth and sustainability.
Under German law, Evotec may pay dividends only from the distributable profit (Bilanzgewinn) reflected in its unconsolidated financial statements (as opposed to the consolidated financial statements for Evotec and its subsidiaries) prepared in accordance with the principles set forth in the German Commercial Code (Handelsgesetzbuch) and adopted by the Evotec Management Board (Vorstand) and the Supervisory Board (Aufsichtsrat), or, as the case may be, by the shareholders of Evotec in a general shareholders’ meeting. In addition, under German law Evotec may not pay dividends before annual profits exceed the losses carried forward.
All of the shares represented by the ADSs offered in USA generally have the same dividend rights as all of Evotec's other outstanding shares.